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ABSTRACT
Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollens is a substantial problem in Japan. Omalizu-
mab, a novel humanized monoclonal anti-immunoglobulin E (IgE) antibody, has already been proven to reduce
symptoms associated with SAR. To investigate the safety and efficacy of omalizumab in the treatment of pa-
tients with Japanese cedar pollen-induced SAR compared to placebo or anti-allergic drug, two randomized,
double-blind studies were conducted in Japan. Omalizumab (150, 225, 300, or 375 mg) or placebo was admin-
istered subcutaneously every 2 or 4 weeks based on serum total IgE and body weight at baseline. IPD was ad-
ministered 300 mg per day through the season. Primary and all secondary efficacy variable scores were signifi-
cantly lower in the omalizumab group than in the placebo group (P < .01) and IPD, Th2 cytokine inhibitor group
(P < .01). Omalizumab was effective and safe in the treatment of SAR induced by Japanese cedar pollens. And
the methods of increasing effects by combining omalizumab with antibody-specific immunotherapy are being
considered. These strategy is more effective than immune-therapy alone.
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INTRODUCTION
Allergic rhinitis including hay fever is a disorder in
which sensitization occurs through the inhalation of
antigens (induction phase), and a local immune reac-
tion then takes place between the antigen-specific IgE
thereby produced and the antigens which have in-
vaded the nasal mucosa (effecter phase). Treatment
for allergic rhinitis depends on suppressing the flow
of this allergic reaction at some point. Antigen-
specific immunotherapy has its point of effect earlier
than midway between the induction phase and effec-
ter phase of allergic reaction, unlike general allergy
medications (antihistamines, chemical mediator re-
lease inhibitors, leukotriene receptor antagonists,
etc.). The anti-IgE antibody omalizumab is also such
a drug whose point of action differs from previous al-
lergy medications.
THE KNOWLEDGE OF ANTI-IgE ANTIBODY
THERAPY
The anti-IgE antibody (omalizumab) produces its ef-
fect by binding to IgE which is not bound to mast
cells, inhibiting it from binding to mast cells. Since
omalizumab does not affect T cells, unlike conven-
tional immunotherapy it is not a curative therapy, but
it is a groundbreaking drug in its application of an im-
munological concept.1
This drug is under application in Japan as indicated
for severe asthma. There is certainly much evidence
for asthma and this is good news for inadequately
controlled asthma. In the field of asthma the concept
of response to omalizumab has already been pub-
lished.2 Currently research is focused on cost-
effectiveness. Medical expenses for asthma in Amer-
ica in 2002 (direct and indirect expenses) totaled 14
billion dollar (direct medical expenses: 3.1 billion dol-
lar for hospitalization, 4.6 billion dollar for drugs).
The cost of omalizumab to improve QOL is 821,000
dollars, and at present cost-effectiveness is not good.
If it could be reduced to 200 dollars or less, it is calcu-
lated that cost-effectiveness would increase.3 How-
ever, in correspondence, D. Revicki argues that the
purely medical cost-effectiveness which is not based
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Fig. 1 The inhibition mechanism of alergic disease by omalizumab. Omalizumab 
was humanized monoclonal antibody against C epsilon 3 portion of Fc epsilon re
ceptor I. Omalizumab blocks the binding between IgE and Fc epsilon receptor I, so 
alergic symptom must be reduced by this mechanism.
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on the Asthma Policy Model is better.4 The cost-
effectiveness will be a large issue in using omalizu-
mab for all allergic disorders in the future.
ANTI-IgE ANTIBODY
In 1991, the American company Genentech produced
an antibody specific to Cε3 that binds to Fcε recep-
tors, in the constant region of human IgE. Omalizu-
mab is a humanized monoclonal antibody using
mouse monoclonal antibody as a base, retaining the
antigen-specific region and replacing the other frag-
ments with human IgGlκ.
When this antibody binds to free IgE in blood by
an antigen-antibody reaction between the Fcε recep-
tor and the Cε3 binding site, an IgE―anti-IgE complex
is formed, and as a result, free IgE is decreased (Fig.
1). Therefore, IgE that binds to mast cells is de-
creased, so that even if antigens invade, binding to
mast cells to form cross-linking is inhibited and aller-
gic reaction is controlled. Another effect is to inhibit
the differentiation of B cells into IgE-producing cells.
This is thought to be because it reacts with
membrane-binding IgE on B cells, inhibiting mRNA
expression of the ε chain. In actual animal experi-
ments, IgE-producing B cells are virtually elimi-
nated.5
EFFECTS OF ANTI-IgE ANTIBODY THERAPY
IN THE US AND EUROPE
In the West, clinical trials of anti-IgE antibody ther-
apy using omalizumab have been conducted for sev-
eral years by subcutaneous injection. The target dis-
orders are allergic rhinitis and atopic asthma, and
clinical trials are being conducted in Japan for the
same targets. In the West, the trials for hay fever dif-
fer from asthma, being conducted at single doses of
150 mg or 300 mg. Casale et al. have reported on a
double-blind comparative trial of those dose levels
plus a placebo and 50 mg for a total of 4 groups, using
American patients with ragweed pollinosis.6 The con-
dition of 300 mg group was better than the placebo
group throughout the pollen dispersal season and at
the peak of pollen dispersal. Lower dose levels also
showed effects, and dose relationship was observed.
Omalizumab also showed significant improvement by
the RQLQ (Juniper’s QOL questionnaire). Similar re-
sults have been obtained for birch pollinosis in the
West, and reduction in drugs for emergency use is
being evaluated (Fig. 2).7
EFFECTSON JAPANESE CEDARPOLLINOSIS
IN JAPAN
Clinical trials were conducted on Japanese cedar pol-
linosis in Japan in 2002 and 2003. The trials of 2002
and 2003 were placebo-controlled comparative study
and comparative study with an anti-allergy drug, re-
spectively.
The placebo-controlled study used a dose concept
of considering the level of omalizumab which can
eliminate IgE systemically, as with asthma in Japan,
in contrast to the overseas studies which have a set
dosage of 300 mg. The amount of omalizumab was
set from body weight and IgE level immediately be-
fore administration in December as 0.0016 mgkg
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Fig. 2 Overseas study of omalizumab for ragweed or 
birch polinosis. Daily nasal severity score in the placebo 
controled study of the patients with ragweed polinosis (ref
erence 6), and birch polinosis (reference 7). Significant re
duction of daily nasal severity score in omalizumab group 
(yelow bar) compared to that in placebo (purple bar) at both 
studies.
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Fig. 3 The change in daily nasal symptom medication score in patients with Japanese 
cedar polinosis in 2002. The nasal symptom medication score was significantly reduced in 
omalizumab group (filed square) in Japanese cedar polen dispersing season in Tokyo 
and Osaka compared to the score in placebo (open square).
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IgE (IUmL) and revised every 4 weeks. Therefore,
IgE was uniformly reduced to the detection limit (50
ngmL) in the administration group. Results of the
study showed omalizumab significantly reduced the
nasal symptom medication score by about 40% for e,
and significantly reduced ocular symptoms by 50%
(Fig. 3). Individual symptoms of Japanese cedar polli-
nosis (itchy nose, sneezing, runny nose, stuffy nose,
itchy eyes, watery eyes, red eyes) were all signifi-
cantly alleviated (Fig. 4). Both nasal and ocular symp-
toms were decreased significantly more than in the
placebo group. The major adverse event was pain at
the injection site. And one case of ulcerative colitis
was reported, but the colitis manifestation is not
thought to be responsible omalizumab application.8
In 2003, an active control study was conducted with
IPD, Th2 cytokine inhibitor. Because the results of
the placebo-controlled study were satisfactory, the
first active control study, double dummy comparative
controlled trial, of omalizumab in the worldwide was
conducted. Dose levels were set to compare omalizu-
mab and IPD using the dose concept. 300 mg per day
of IPD was administered initial treatment from begin-
ning of February, and through the season. The nasal
symptom medication score during the pollen disper-
sal season was 30% lower than IPD (Fig. 5). In indi-
vidual symptoms, omalizumab was more effective
than IPD for sneezing, runny nose and stuffy nose, al-
though there were no significant differences in itchy
nose or ocular symptoms. Omalizumab was more ef-
fective to the same degree through the pollinating
season including the high pollen dispersal season,
and there were no adverse reactions.9
Omalizumab is currently under application at the
Ministry of Health, Labour and Welfare for severe
asthma, but application for hay fever has not been
made. This may be because it is not a life-threatening
illness, and since there are many patients, recogni-
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Fig. 4 The change in daily nasal and ocular symptom score in patients with Japa
nese cedar polinosis in 2002. Al symptoms score, sneezing, runny nose, stufy 
nose, itchy nose, itchy eyes, watery eyes, and red eyes, were significant reduced 
in omalizumab group (purple bar) compared with the score in placebo (yelow bar), 
especialy in eye symptoms.
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Fig. 5 The daily nasal symptom medication score in com
parative study between omalizumab (E25) and IPD for pa
tients with Japanese cedar polinosis in 2003. Nasal 
symptom medication score was evaluated in three periods 
such as study period, polen dispersing period (polen sea
son), peak polen dispersing period (peak season). In al 
three period, nasal symptom medication score with omalizu
mab (E25) group (grey bar) was reduced compared to the 
score with the placebo (orange bar).
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tion of the indication could lead to improper use. At
any rate, application for allergic rhinitis, including
Japanese cedar pollinosis has not been made in any
country, but if with advances in technology lower
costs for antibody manufacturing and means of reduc-
tion to safer numbers can be attained, the treatment
for hay fever will become broader in Japan in the fu-
ture.
OTHER USES FOR ANTI-IgE THERAPY
Overseas, methods of increasing effects by combin-
ing omalizumab with antibody-specific immunother-
apy are being considered. Wahn et al. conducted an
RCT in children with sensitization to birch and grass
pollen using immunotherapy for either in combina-
tion with omalizumab, and the symptom scores for
each immunotherapy were further reduced by half.10
In a study of the same group, leukotriene release by
antigen stimulation after the pollen dispersal season
that was not reduced by immunotherapy alone was
suppressed. However, this suppression reverts back
one month after treatment.11 Klunker et al. described
combination with rush immunotherapy against rag-
weed pollinosis. In this study omalizumab administra-
tion was begun 9 weeks before the start of rush im-
munotherapy, with improved effects. This idea is in
accordance with the idea of administering omalizu-
mab before the advent of symptoms in the Japanese
clinical study. There were no differences in the symp-
tom scores of omalizumab alone and rush immuno-
therapy combined with omalizumab, but the ability of
B cells to bind with allergen-IgE complexes was in-
hibited more than by rush immunotherapy alone.
That is, omalizumab was shown to inhibit CD23 ex-
pression in B cells for 30 weeks after completion of
immunotherapy at week 42.12
A study on nasal polyps was also conducted. Penn
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et al. performed endoscopic surgery on nasal polyps
complicated by allergic asthma and allergic rhinosi-
nusitis, and observed the course of omalizumab ad-
ministration thereafter. Recurrence was 25% with and
without omalizumab (14), but the number of cases
was small, and the effects have not been completely
verified.13,14
THE FUTURE
In the field of allergies there are few illnesses in
which IgE does not play a role, and the time may be
coming when the use of omalizumab will be consid-
ered for all disorders whose pathology has some in-
volvement of IgE. There are many problems that
need to be overcome, including that of cost. How-
ever, as it is, reduction of IgE can improve the clinical
condition in almost all allergic disorders, and we
must demonstrate in Japan as well that the current
application of omalizumab can be expanded to other
indications.
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